Clinical ink, a company specializing in life science technology, has announced a strategic partnership with The Boston Clinical Research Institute (BCRI), an Academic Research Organization (ARO) based in Boston, Massachusetts. By joining forces, BCRI's expertise in clinical strategy, therapeutic area knowledge, and academic collaboration will be combined with Clinical ink's eSource technology, which includes Direct Data Capture (DDC), electronic Clinical Outcomes Assessments (eCOA), and digital biomarkers.
BCRI offers scientific consulting in study design, patient-centered modalities, endpoint selection, and complex data analysis, leveraging expert clinicians and key opinion leaders from renowned medical institutions. Its aim is to help advance global health and quality of life. To date, the institute has overseen 450 studies with over 160,000 patients enrolled, and has been involved in more than 50 FDA submissions.
"We are thrilled to announce this partnership," said Michael Gibson, MD, President and Chief Executive Officer of BCRI. "Expert design and planning by therapeutic thought leaders who recommend the implementation of innovative and clinically-relevant eSource technology will pave the way forward for global clinical trials."
Dr. Jonathan Goldman, MD, the Chief Executive Officer of Clinical ink, added, "We are excited that Dr. Gibson and BCRI have joined forces with Clinical ink. This collaboration will provide our trusted Sponsor and CRO partners with access to a wide range of clinical and key opinion leader expertise in trial design, as well as clinical and digital endpoint selection across a full range of therapeutic areas."
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special
offers from Pharmaceutical Outsourcing – all delivered right to your inbox! Sign up now!